Mesoblast

Mesoblast

A regenerative medicine company developing biologic products for inflammatory ailments, cardiovascular disease and back pain

Mesoblast has an intellectual property portfolio of more than 1000 patents or patent applications including the use of mesenchymal stem cells/mesenchymal stromal cells (MSCs) for treatment of patients with acute respiratory distress syndrome (ARDS), inflammatory lung disease due to COVID-19, influenza and other viruses.

Their MSC product called Remestemcel-L is being testing in clinical trials for inflammatory conditions including elderly patients with lung disease and adults and children with steroid-refractory acute graft-vs.-host disease (aGVHD). Mesoblast’s stem cell therapy is under review by the FDA for treatment of children with steroid-refractory aGVHD. Remestemcel-L is being developed for rare pediatric and adult inflammatory conditions. The product is comprised of culture-expanded MSCs derived from bone marrow of an unrelated donor (allogeneic) that is administered in a series of intravenous infusions. The therapy is thought to have immunomodulatory properties which counteract inflammatory processes including down-regulation of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines and enabling recruitment of anti-inflammatory cells already in the body to the diseased tissue. Remestemcel-L is previously known under the product name Prochymal by the company Osiris Therapeutics. In 2013 Mesoblast acquired Prochymal and Osiris’ culture-expanded mesenchymal stem cell business.

As of March 2020, Mesoblast has plans to evaluate its allogeneic mesenchymal stem cell (MSC) candidate, remestemcel-L in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 in the US, Australia, China and Europe. ARDS is the and immune system overreaction to the virus in the lungs that causes severe damage to lung tissue. Allogeneic MSCs have been reported to cure or significantly improve functional outcomes of seven treated patients with severe COVID-19 pneumonia in a clinical study in China. Remestercel-L infusions have been tested on patients with chronic obstructive pulmonary disease (COPD) shown to be well tolerated, reduce inflammatory biomarkers and improve pulmonary function in patients with elevated inflammatory biomarkers. The same inflammatory markers are elevated in patients with ARDS due to COVID-19.

Timeline

November 11, 2020
Mesoblast Limited announces randomized controlled Phase 3 trial of remestemcel-L in patients with moderate to severe acute respiratory distress syndrome (ARDS).
2004
Mesoblast was founded by Silviu Itescu.

People

Name
Role
LinkedIn

Darian Edvalson

Employee

Larry Cheng

Employee

Lee Golden

Employee

Ljiljana Minwalla, J.D., Ph.D.

Employee

Michael Taub

Employee

Nikoletta Toth

Employee

stephen klincewicz

Employee

Further reading

Title
Author
Link
Type
Date

Phase 3 Trial of Mesoblast's Cell Therapy in Chronic Heart Failure Completes Recruitment

Mesoblast Limited

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Phil Taylor
December 18, 2020
FierceBiotech
Australian biotech Mesoblast has been riding high on expectations for its COVID-19 treatment, licensed to Novartis, but fell back to Earth after it said a phase 3 trial of the cell therapy was a bust.
Pomerantz LLP
December 5, 2020
www.prnewswire.com:443
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO) and...
Rosen Law Firm, P.A.
November 28, 2020
www.prnewswire.com:443
/PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16,...
Mark Terry
November 20, 2020
BioSpace
Novartis inked an exclusive worldwide license and collaboration deal with Australia-based Mesoblast to develop, commercialize and manufacture remestemcel-L for acute respiratory distress syndrome (ARDS), including when it is linked to COVID-19.
Nick Paul
November 20, 2020
FierceBiotech
Novartis has secured a global license to Mesoblast's cell therapy remestemcel-L in the treatment of COVID-19. The deal lands Mesoblast $50 million upfront and the support of a partner that could help address critical quality attribute concerns raised by the FDA.
Rosen Law Firm, P.A.
November 14, 2020
www.prnewswire.com:443
/PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16,...
BioSpace
November 11, 2020
BioSpace
Mesoblast Limited announced that the randomized controlled Phase 3 trial of remestemcel-L in patients with moderate to severe acute respiratory distress syndrome due to COVID-19 infection had received a recommendation to continue from the independent Data Safety Monitoring Board following completion of the trial's second interim analysis.
Knvul Sheikh
April 8, 2020
news.google.com
Just three months after the start of the coronavirus pandemic, several biotech companies are beginning trials of promising vaccines and treatments.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.